GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.

COVID-19: Targeting Better Efficacy, China Trials Mixing CanSino and Zhifei Longcom Vaccines

by Tyler Chen
Share To

Under the pressing need for more effective COVID-19 vaccinations, China has begun examining the efficacy of mixing two approved vaccines. The country is evaluating the combination of CanSino Biologics’ Ad5-nCoV (Convidecia) and Anhui Zhifei Longcom Biopharmaceuticals’ ZF2001 (RBD-Dimer).

Efficacy Evaluations in Two Interval Settings

Sponsored by the Jiangsu province centers for disease control and prevention in China, the trial recruited 120 healthy subjects who received one dose of Ad5-nCoV on day 0. Then, half of the subjects will receive a booster dose of either ZF2001 or trivalent split influenza vaccine on day 28 with the ratio of 2:1; the other half will be put under the same regime but with the interval of 56 days.

Scientists will primarily look at the incidence of solicited adverse events within 7 days after vaccination and geometric mean titer (GMT) of neutralizing antibodies against SARS-CoV-2 at day 14 after the booster vaccination. The trial will last for 6 months according to the clinical records on ClinicalTrials.gov.

Ad5-nCoV: 68% Efficacy with One Shot

Ad5-nCoV is the only single shot COVID-19 vaccine to be approved in China. As stated in the interim report of a Phase 3 clinical trial, the vaccine registered a 68.83% efficacy 14 days after administration. In 28 days, the number fell to 65.28%.

Currently, the vaccine is not approved in the US, but it has been granted accelerated approval in five countries, including China, Chile, Mexico, Pakistan, and Hungary. The five vaccines that are currently approved in China are all locally developed and produced.

CanSino Pushes for Inhaled Vaccine

According to Co-Founder and Chief Executive Officer Xuefeng Yu, CanSino Biologics is now working on an inhaled version of its COVID-19 vaccine with the help of the Beijing Institute of Biotechnology. An inhaled vaccine might add more protection than an injected one considering the airway is the first stop of SARS-CoV-2 entering the body. The clinical trial is expected to begin next week.

With that, CanSino Biologics will have a chance to compete with the global vaccine market since Pfizer/BioNTech, Moderna, AstraZeneca, and Johnson & Johnson vaccines demonstrated stronger protection than Ad5-nCoV.

Related Article: The Accessibility of Point-of-Care COVID-19 Detection Tests: Why Care?

 

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
LATEST
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top